MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain

Cell Death and Disease

Volumn 5, Issue 4, 2014, Pages

  Li, Q ^a   Wang, J X ^a   He, Y Q ^b   Feng, C ^a   Zhang, X J ^a   Sheng, J Q ^b   Li, P F ^a,c  

^a INSTITUTE OF ZOOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

ARC; Chemosensitivity; Gastric cancer; MiR 185; RUNX3

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; APOPTOSIS REPRESSOR WITH CASPASE RECRUITMENT DOMAIN; CISPLATIN; DOXORUBICIN; MICRORNA; MICRORNA 185; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; MIRN185 MICRORNA, HUMAN; MUSCLE PROTEIN; NOL3 PROTEIN, HUMAN; RUNX3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER TISSUE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA TRANSCRIPTION; STOMACH CANCER; TUMOR XENOGRAFT; ADULT; AGED; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MALE; MICE, NUDE; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUSCLE PROTEINS; STOMACH NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84901051015     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.148     Document Type: Article

References (45)

1. Milne AN, Carneiro F, O'morain C, Offerhaus G. Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 2009; 126: 615-628.
2. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000; 57: 1229-1235.
3. Longley D, Johnston P. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292.
4. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005; 436: 214-220.
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
6. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. The miR-15a- miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-1277.
7. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688.
8. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y-J, Ngankeu A et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2011; 18: 74-82.
9. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, Van Rooij E et al. Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. Cancer Cell 2010; 18: 282-293.
10. Koseki T, Inohara N, Chen S, Núnẽz G. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc Natl Acad Sci 1998; 95: 5156-5160.
11. Ludwig-Galezowska AH, Flanagan L, Rehm M. Apoptosis repressor with caspase recruitment domain, a multifunctional modulator of cell death. J Cell Mol Med 2011; 15: 1044-1053.
12. Mercier I, Vuolo M, Jasmin J-F, Medina CM, Williams M, Mariadason JM et al. ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle 2008; 7: 1640-1647.
13. Mercier I, Vuolo M, Madan R, Xue X, Levalley A, Ashton A et al. ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo-and radiation-resistance. Cell Death Differ 2005; 12: 682-686.
14. Wang J-X, Li Q, Li P-F. Apoptosis repressor with caspase recruitment domain contributes to chemotherapy resistance by abolishing mitochondrial fission mediated by dynaminrelated protein-1. Cancer Res 2009; 69: 492-500.
15. Li P-F, Li J, Müller E-C, Otto A, Dietz R, von Harsdorf R. Phosphorylation by protein kinase CK2: a signaling switch for the caspase-inhibiting protein ARC. Mol Cell 2002; 10: 247-258.
16. Tan W-Q, Wang J-X, Lin Z-Q, Li Y-R, Lin Y, Li P-F. Novel cardiac apoptotic pathway: the dephosphorylation of apoptosis repressor with caspase recruitment domain by calcineurin. Circulation 2008; 118: 2268-2276.
17. Li Y-Z, Lu D-Y, Tan W-Q, Wang J-X, Li P-F. P53 initiates apoptosis by transcriptionally targeting the antiapoptotic protein ARC. Mol Cell Biol 2008; 28: 564-574.
18. Lu D, Liu J, Jiao J, Long B, Li Q, Tan W et al. Transcription factor Foxo3a prevents apoptosis by regulating calcium through the apoptosis repressor with caspase recruitment domain. J Biol Chem 2013; 288: 8491-8504.
19. Foo RS-Y, Chan LK, Kitsis RN, Bennett MR. Ubiquitination and degradation of the antiapoptotic protein ARC by MDM2. J Biol Chem 2007; 282: 5529-5535.
20. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA et al. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood 2011; 117: 780-787.
21. Braun T, Woollard A. RUNX factors in development: Lessons from invertebrate model systems. Blood Cells Mol Dis 2009; 43: 43-48.
22. Li Q-L, Ito K, Sakakura C, Fukamachi H, Inoue K-i, Chi X-Z et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113.
23. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
24. Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J. MiR-107 and MiR- 185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 2009; 4: e6677.
25. Medina-Ramirez CM, Goswami S, Smirnova T, Bamira D, Benson B, Ferrick N et al. Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance. Cancer Res 2011; 71: 7705-7715.
26. Yano T, Ito K, Fukamachi H, Chi X-Z, Wee H-J, Inoue K-i et al. The RUNX3 tumor suppressor upregulates bim in gastric epithelial cells undergoing transforming growth factorb-induced apoptosis. Mol Cell Biol 2006; 26: 4474-4488.
27. Yamada C, Ozaki T, Ando K, Suenaga Y, Inoue K-i, Ito Y et al. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a coactivator for p53. J Biol Chem 2010; 285: 16693-16703.
28. Liu M, Lang N, Chen X, Tang Q, Liu S, Huang J et al. miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells. Cancer Lett 2011; 301: 151-160.
29. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A et al. Identification of metastasisrelated microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897-907.
30. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009; 4: e5311.
31. Imam J, Buddavarapu K, Lee-Chang J, Ganapathy S, Camosy C, Chen Y et al. MicroRNA- 185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 2010; 29: 4971-4979.
32. Tang H, Wang Z, Liu X, Liu Q, Xu G, Li G et al. LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. Curr Cancer Drug Targets 2012; 12: 1032-1042.
33. Qu F, Cui X, Hong Y, Wang J, Li Y, Chen L et al. MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor. Mol Cell Biochem 2013; 377: 1-10.
34. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2013; 33: 378-386.
35. Yoon JH, Choi YJ, Choi WS, Ashktorab H, Smoot D, Nam SW et al. GKN1-miR-185- DNMT1 axis suppresses gastric carcinogenesis through regulation of epigenetic alteration and cell cycle. Clin Cancer Res 2013; 19: 4599-4610.
36. Ho JD, Metcalf JL, Yan MS, Turgeon PJ, Wang JJ, Chalsev M et al. Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J Biol Chem 2012; 287: 29003-29020.
37. Farazi TA, Horlings HM, Jelle J, Mihailovic A, Halfwerk H, Morozov P et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 2011; 71: 4443-4453.
38. Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H et al. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis 2010; 31: 208-215.
39. Peng Z, Wei D, Wang L, Tang H, Zhang J, Le X et al. RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res 2006; 12: 6386-6394.
40. Chi X-Z, Kim J, Lee Y-H, Lee J-W, Lee K-S, Wee H et al. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res 2009; 69: 8111-8119.
41. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell-delivered S-TRAIL in human gliomas. Cancer Res 2007; 67: 8994-9000.
42. Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C et al. Anti-microRNA-222 (anti-miR-222) and-181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 2011; 286: 42292-42302.
43. Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS et al. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Therap 2012; 11: 2556-2565.
44. Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li P-F. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci USA 2009; 106: 12103-12108.
45. Wang J-X, Jiao J-Q, Li Q, Long B, Wang K, Liu J-P et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med 2010; 17: 71-78.